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RV and pencardium, have also been proposed as a mechanism of benefit from CRT. We 
set out to determine if the presence of a restrictive mitral filling pattern, known to be a 
marker of DVI, might identify patients more likely to respond to BVP. 
Methods: 19 patients with severe heart failure, LBBB (QRS >lZOms) and fractional short- 
ening (FS%) ~25% were studied before and 6 months after CRT. 
Results: NYHA class improved from 3.4+/-0.3 to 2.3 +/-0.5 (p=O.OOl) after pacing. 
Patients were divided into responders (n=lO, 53%) and non-responders (n=9, 47%) 
based on >5% improvement in FS after pacing. E/A had a stronger correlation than base- 
line QRS with response (r=O.72, p=O.OOl). and remained strongly related when consid- 
ered in combination with other variables. An E/A ~2.0 had a sensitivity of 70% specificity 
of 100% and a predictive value of 100% for determining a positive response to pacing. 
Response to pacing was associated with a significant reduction in E/A (p=O.O3). 
Conclusions: Patients with restrictive mitral Doppler filling patterns (marker of DVI) are 
more likely to show improvements in LV systolic function after CRT. By permitting the LV 
to fill before the RV thus ameliorating DVI. CRT may allow improved LV filling and LV 
systolic function. 
duration and LV volumes was assessed using Kruskall-Wallis non-parametric testing. 
Results: Mean LV EF was 29 f 8 %, mean LV end diastolic volume (EDV) was 200 * 75 
ml, mean LV end systolic volume (ESV) was 146 * 60 ml and mean QRS duration was 
125 r 30 ms. Pts with longer QRS duration had highly significant lower LV EF (p=O.OOZ) 
and higher LV end diastolic and end systolic volumes (both p < 0.001). Means and 95 % 
confidence intewals for LV EF. LV EDV and LV ESV are shown in the figure. 
Conclusion: In patients with heart failure due to CAD, QRS duration on the resting ECG 
is strongly related to LV volumes and LV EF. Therefore, QRS duration is an easily obtain- 
able marker of possible LV dilatation in these patients. 
1110-74 Left Ventricular Pacing Recruits Preload Reserve in 
Heart Failure Patients: A New Mechanism 
Rob A. Bleasdale, M. S. Turner, C. E. Mumford, Paul Steendijk, V. E. Paul, J. A. Morris- 
Thurgood, M. P. Frenneaux. Wales Heart Research Institute, Cardiff, United Kingdom, 
Leiden University Medical Center, The Netherlands 
Left ventricular pacing (LVP) is thought to improve cardiac function primarily by systolic 
resynchronisation. Our observation that patients with a short QRS duration also benefit 
from LVP suggests alternative mechanisms may also be involved. We hypothesised that 
LVP may influence diastolic filling by inducing a phase shift where by the LV filling occurs 
before right ventricular filling and that this would result in a beneficial reduction in exter- 
nal constraint to LV filling. We present data from 9 heart failure patients with mean left 
ventricular end diastolic pressure (LVEDP) of 21 .S*lOmmHg and QRS duration of 
143+34ms (range, 60-162ms). Simultaneous invasive, micro manometer pressure and 
conductance catheter volume analysis were performed to assess the end diastolic pres- 
sure volume relation during acute right ventricular volume unloading by inferior vena 
caval occlusion. External constraint is defined as the amount by which the LVEDP can be 
reduced without reducing LV end diastolic volume (LVEDV). During LVP, external con- 
straint was reduced from 6.2+4.6mmHg to 3.1+3.7mmHg (p<O.Ol). This removal of 
external constraint by LVP resulted in a 4.1+3.3% increase in LVEDV (p=O.O17), which 
occurred without a slgniflcant rise in LV end systolic volume (0.2+6.5%, pEO.94) resulting 
in an increase in stroke volume of 12.5*11% (p=O.O4). This improvement in stroke vol- 
ume was associated with a rise in dpidt max from 659.7+371 to 767r316 (p=O.O5). We 
conclude that the relief of external constraint to LV filling improves the effective preload 
and allows the use of the Frank-Starling mechanism to improve contractile function and 
cardiac output, of particular potential importance during exercise. 
1110-75 Relationship Between 0% Duration and Left 
Ventricular Volumes in Patients With Heart Failure Due 
to Coronary Artery Disease 
Olivier De Winter, Johan De Sutter, Geerl Van Pottelberghe. Frederic Van Heuverswyn, 
Rudi A. Dierckx, Thierry Gillebert. Ghent University Hospital, Ghent, Belgium 
Backaround: Both QRS duration and left ventricular (LV) volumes provide prognostic 
information in patlents with heart failure due to coronary artery disease (CAD). The aim 
of this study was to investigate a possible relationship between these parameters. 
Methods: We investigated 277 consecutive patients (246 males, age 65 + 10 years) with 
CAD and LV ejection fraction (EF) < 40 %. All patients underwent a stress-rest myocar- 
dial perfusion gated SPECT study: LV volumes and EF in resting condition were deter- 
mined using QGS” software (Cedars-Sinai, LA, California). QRS duration was measured 
from the resting ECG. Patients were categorized in 6 groups according to QRS duration 
(~100; 100-119; 120-139; 140-159; 160-179; 2160 ms). Relationship between QRS 
1110-76 Plasma Neurohormonal Changes in Response to 
Cardiac Resynchronization Therapy in Patients With 
Congestive Heart Failure 
Guide Boerdater, Susan C. Madden, Lisa C. Costello-Boerrigter. Alessandro Cataliotti, 
Denise M. Heublein, William T. Abraham, Michael R. Hill, John C. Burnett. Jr., Mayo 
Clinic, Rochester, MN, Medtronic, Inc., Minneapolis, MN 
Background: Cardiac resynchronization (CR) pacing therapy as evaluated in the Multi- 
center InSync Randomized Clinical Evaluation (MIRACLE) trial has been shown to result 
in symptomatic improvements in patients with overt heart failure and ventricular dysyn- 
chrony. Neurohormonal (NH) activation during CR was evaluated, recognizing that NH 
mechanisms may serve as prognostic indicators of patient status and/or ventricular 
remodeling. 
Methods: NH measurements were perfomed at baseline prior to implantation of an atrial 
synchronous biventricular pacing device. Patients were randomized to control pacing off 
(C, n=225) or treatment pacing on (P, n=226) groups. NHs were repeated at 3 and 6 
months. Tests included brain natriuretic peptide (BNP), cyclic guanosine monophosphate 
(cGMP), norepinephrine. epinephdne, dopamine, big endothelin (BigET), tumor necrosis 
factor, plasma renin activity and aldosterone. Differences between groups were analyzed 
by Mann-Whitney-U; changes within groups by Wilcoxon’s rank sum test (p.zO.05 consid- 
ered significant). 
Results: There were no significant baseline differences in NHs between groups. 
Changes in NHs at 3 months were not significant between groups. Changes in NHs at 6 
months between groups were significant for cGMP only (p=O.OZ). Significant within group 
changes at 3 months showed decreased BNP in P (p=O.O19); increased BigET in C 
(p.zO.01) and P (p=O.O4). Significant within group changes at 6 months showed 
decreased BNP in C (peO.01) and P (pcO.01); decreased cGMP in P (p=O.OZ): and 
increased BigET in C (pcO.01) and P (p<O.Ol). 
Conclusion: In this patient population, cGMP was significantly reduced in the paced 
group at 6 months suggesting a potential reduction in natriuratic peptide activation. Other 
NHs appeared to respond similarly over time between groups. At 6 months these results 
suggest that these NHs are not significantly changed in response to CR. 
1110-77 Chronic Therapy With the Acorn Cardiac Support 
Device Reduces Gene Expression of MMP2 and MMP9 
in Dogs With Heart Failure 
Sharad Rastoqi Ramesh C. Gupta, Sudhish Mishra. Hideaki Morita, Hani N. Sabbah, 
Henry Ford Health System, Detroit, MI 
Background: Accumulation of collagen in the cardiac lnterstitium (reactive interstitial 
fibrosis, RIF) occurs in heart failure (HF) and contributes to LV dysfunction. Matrix metal- 
loproteinases (MMPs) are upregulated in HF and can mediate RIF. In dogs with HF, the 
Acorn Cardiac Support Device &SD), a preformed polyester device surgically placed 
over the ventricles, was shown to reduce LV volume and increase ejection fraction. We 
also showed that chronic CSD therapy reduces RIF and preserves matrix cross-link 
(MCL) integrity in dogs with HF. This study examined the effects of the CSD on gene 
expression of MMP2 and 9 (gelatinases) and on tissue inhibitors of MMPs (TIMPs). 
Methods: The CSD was implanted in 6 dogs with microembolization-induced HF. Six 
other HF dogs sewed as controls. All dogs were followed for 3 months. LV tissue from all 
HF dogs and 6 normal (NL) ddgs was used to extract total RNA. mRNA expression for 
MMPZ and 9 and TlMPl and 2 was measured using teverse transcriptase polymerase 
chain reaction and bands quatified in densitometric units. Results: Results ate shown in 
the table.There were no differences in expression of TlMPl and 2 among the groups. 
Expression of MMPP and 9 was upregulated in HF compared to NL. Therapy with the 
CSD reduced expression of MMP2 and 9 compared to HF controls. Conclusions: 
Chronic therapy with the CSD does not influence TlMPs but reduces expression of 
MMPP and 9. a finding consistent with reduced RIF and preserved MCL integrity I” dogs 
with HF followmg chronic CSD therapy. 
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TIMPI 
TIMPP 
MMP2 
MMPQ 
NL HF-Untreated HF +CSD 
1.26 + 0.23 I.382 0.35 1.68 0.44 + 
2.70 + 0.13 2.542 0.33 2.90+0.11 
0.86 + 0.09 1.65+0.04’ 1.16+0.14” 
0.56 + 0.07 1.512 0.05’ 0.96 0.11” + 
*=P<O.O5 vs. NL; “=P<O.O5 vs. HF.Untreated 
1110-78 Ventricular Arrhythmias Following Autologous Skeletal 
Myoblast Implantation 
Warren Sherman, Kun-Lun He, Geng-Hua Yi, Hua Zhou. Angou Gu, Eva M. Becker, Ge- 
Ping Zhang, Jack Harvey, Race Kao. Myung J. Lee, Jle Wang, Howard Haimes, Daniel 
Burkhoff, Mount Sinai School of Medicine, New York, NY, Columbia University School of 
Medicine, New York, NY 
Background: Cellular cardiomyoplasty using autologous skeletal myoblasts (ASM) has 
been proposed as treatment for congestive heart failure (CHF). Early clinical use of this 
technique has raised concerns regarding the incidence of ventricular tachyarrhythmias 
and sudden death. We performed ambulatory monitoring in dogs with CHF after receiv- 
ing ASM injections. 
Methods: 15 dogs underwent induction of CHF by coronary microembolization. After 4 
weeks, injections of ASM (280.780 million ceils) or saline were delivered by either open- 
chested epicardial (EPI) or transcatheter endoventricular (ENDO) methods. Multiple 24 
hour ambulatory ECGs (AECG) were recorded at baseline (preinjection) and at weeks 4. 
8 and 10 after injection. AECGs were reviewed for VT Unexpected terminal events were 
tabulated. 
Resul1s: Four groups of dogs were identified: ASM/EPI (5), ASM/ENDO (4), saline/EPl 
(3), and saline/END0 (3). 73 interpretable AECG were evaluated. Occurrences of ven- 
tricular tachycardia (VT) or death (Dj are as belpw. The majority of events were obsewed 
in 6 of 15 dogs. There was no relationship between VT and #cells injected or #injections 
par dog. 
Conclusion: In this model of myocardial dysfunction and cellular cardiomyoplasty. the 
injection of ASM did not result in an increase in death or ventricular tachycardia during 
the monitored periods. 
Events Afier lqectmn (Ventncular Tachycardia or Death) 
Injection 
Event 
Baseline 
Week 4 
Week 8 
Week IO 
TOTAL 
ASM EPI 
VT ... ..D 
0.. .... .o 
12 ... ..I 
21 ... ..o 
0.. .... .o 
33 ... ..I 
ASM END0 
VT ... ..D 
0.. .... .o 
0.. .... .o 
0.. .... .o 
272 .. ..O 
272 .. ..O 
Saline EPI 
VT ... ..D 
113 .. ..o 
0.. .... .l 
0.. .... .o 
328 .. ..O 
441 .. ..l 
Saline END0 
VT ... ..D 
5.. .... .o 
0.. .... .o 
0.. .... .o 
0.. .... .o 
5.. .... .o 
1110-79 Contractile Response and Mitral Regurgitation After 
Late Withdrawal of Biventricular Pacing 
Roland R. Brana Christian Reiner, Johannes Sperzel. Heinz F. Pitschner. Christian W 
Hamm, Kerckhoff Heart Center, Bad Nauhelm, Germany 
Background: Biventricular pacing @VP) is a promising treatment modality for patients 
with symptomatic heart failure (HF) and mechanical dyssynchrony in the setting of left 
bundle branch block or intraventricular conduction delay. Clinical studies have shown 
short-term improvement in contractile function and long-term improvement in clinical sta- 
tus in association with reverse left ventricular (LV) remodeling. The aim of this study was 
to investigate the hemodynamic consequences of late biventricular pacing (BVP) with- 
drawal. 
Methods: Eleven patients (6459 years) received a BVP system because of severe HF 
(NYHA class Ill) due to idiopathic (1x6) or ischemic (n=3) LV dysfunction and a QRS 
interval >150 msec. Patients were studied 459+259 days after continuous BVP. Thereaf- 
ter, the BVP mode was deactivated (Off) and patients were restudied after an equilibra- 
tion period of 72 hours on constant medication. The rate of LV pressure rise (dPldt) was 
estimated by measuring the time intewal between 1 and 3 mlsec on the mitral regurgita- 
tion (MR) continuous-wave Doppler spectrum. MR severity was assessed with the color 
Doppler jet area and effective regurgitant orifice area (ERO) derived from the PISA 
method. 
HR Meanblood 
(I pressure(mm 
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9 
Conclusion: Late withdrawal of biventricular pacmg leads to a de&e m LV systolic per- 
formance and an increase in functional MR despite a lower blood pressure. These results 
indicate a sustained long-term hemodynamic benefit of biventricular pacing independent 
of a rswrse LV remodeling process. 
1110-80 Impact of Cardiac Resynchronization on Mortality From 
Progressive Heart Failure 
DavidJ. Bradley, Elizabeth A. Bradley, Kenneth Lee Baughman, Ronald D. Berger, Hugh 
Calkins, Steven N. Goodman. David A. Kass. Neil R. Powe, Johns Hopkins Medical 
Institutions, Baltimore, MD 
Background: Cardiac resynchronization improves cardiac function, exercise capacity, 
and quality of life among heart failure patients. The effect of cardiac resynchronization on 
mortality from progressive heart failure, however, is uncerlain. To determme whether car- 
diac resynchronization decreases mortality from progressive hearl failure, we conducted 
a meta-analysis of randomized trials. 
Methods: Medline, Embase, and the Cochrane Controlled Trials Register were searched 
for reports of randomiied controlled trials of cardiac resynchronization for the treatment 
of chronic symptomatic left ventricular dysfunction among patients with prolonged QRS 
intervals. Eligible studies had at least three months of follow-up. Reports of crossover tri- 
als were excluded if the first randomized crossover phase was less than three months. 
Trials were rewewed independently by two investigators. Trial data were pooled using a 
random effects statistical model. 
Results: Outcomes from trials with 1634 total patients were included in the meta-analy- 
sis. Baseline patient characteristics were similar in the included trials, and the majority of 
patients were men with moderate to severe heart failure symptoms at baseline (New 
York Heart Association functional class Ill and IV) and prolonged QRS intervals. Pooled 
data showed that progressive heart failure mortality was 1.7% for cardiac resynchroniza- 
tion patients and 3.5% for controls over three to six months of follow-up. Cardiac resyn- 
chronization reduced death from progressive heart failure by 51% relative to controls (p = 
0.029). There was not evidence of quantitative heterogeneity by a chi-square test 
(p=O.85), suggesting a consistent effect across trials. 
Conclusions: Cardiac resynchronization appears to reduce mortality from progressive 
heart failure over three to six months of follow-up in patients with symptomatic left ven- 
tricular dysfunction and prolonged ORS intervals. This finding suggests that cardiac 
resynchronization may have a positive Impact on the most common mechanism of death 
among patients with advanced heart failure. 
11 IO-81 Acute Hemodynamic Effects of Pacing Therapy on Left 
Ventricular Function in Patients With Heart Failure and 
Atrial Fibrillation: Comparison of Left Ventricular 
Pacing and Biventricular Pacing 
Taro Okada, Yukihiko Yoshida. Makoto Kondo, Kosuke Watanabe, Masahiro Mutoh, 
Takumi Yamada. Tomomitsu Tani, Shoji Yamakami, Kazuki Iwata, Yoshimasa 
Murakami, Toyoaki Matsushita, Mitsuhlro Okamoto. Naoya Tsuboi, Haruo Hirayama, 
Teruo Itoh, Junji Toyama. Owari Hospital. IchinomiyaGity, Japan, Nagoya Daini Red- 
Cross Hospital, Nagoya-City. Japan 
Background: It has been reported that both biventricular pacing (BVP) and left ventricu- 
lar pacing (LVP) similarly improve lefi Ventricular (LV) function in patients with heart fail- 
ure and sinus rhythm (S). However it is not clear which pacing mode may be preferable 
in patients with heati failure and atrial fibrillation (AF). 
Methods: Hemodynamic parameters were studied in 18 patients (Mean&EM: QRS 
duration 178iQms. LVEF 25.7*1.6%). Patients were stimulated in either the VVI mode (7 
patients with AF) or the DDD mode (11 patients with S) at a rate of QObpm. Ventricular 
pacing was given in the right ventricular apex, LV lateral free wall via coronary sinus, and 
both ventricles simultaneously. In patients with AF, data under baseline rhythm were 
compared with pacing at varying ventricular sites. In patients with S, atrioventricular inter- 
val was decreased by 20ms decrements from 200 to 60 ms for 3 minutes each and opti- 
mal atrioventricular interval with the largest dpidtmax was determined at varying pacing 
sites. Data under AAI pacing at 90 bpm were compared with DDD pacing at varying ven- 
tricular sites with each optimal atrioventricular interval. 
Results: In patients with AF, right ventricular pacing (RVP) had negligible contractile 
effects. However, LVP and BVP raised dp/dtmax by 25.5*3.1% and 21.4+4.3%, respec- 
tively (P<O.Ol and P<O.Ol, versus RVP 4.1*3.5%).The data was similar in patents with S 
(LVP 34.9+4.5%, BVP 31.0+4.6%, RVP -1.2+3.2%). With regard to LV diastolic funCtiOn, 
there was no improvement during RVP and LVP, however significant improvement was 
observed during BVP in patients with AF. BVP Improved dpldtmin by 19.1*1.3% 
(P<O.OOl versus RVP 6.1*3.2% and LVP 2.6+1.2%), and pressure half time by 
20.1&.9% (P<O.Ol versus RVP 5.7*2.7% and LVP -1.2+1.9%). In patients with S, DDD 
